Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

NCT ID: NCT00492765

Last Updated: 2010-10-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 380 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-02-28
• Study Completion Date: 2010-04-30

Brief Summary

This study is to find out if there is any benefit to adding Simvastatin to Interferon-beta-1a in patients with Multiple Sclerosis.

Detailed Description

This is a multi-centre, double blind, placebo controlled, randomised, parallel group, phase 4 study. Following three months treatment with Interferon beta 1a (Avonex) patients will be randomised for treatment with simvastatin or placebo as an add-on to interferon -beta-1a (AvonexÒ). Patients will start treatment with 40 mg peroral simvastatin daily or identically appearing placebo for one month. Hereafter, patients will escalate dosage to 80 mg daily. The patients will be examined clinically at baseline and at, 3, 4, 6, 9, 12 and 15 months. Patients who attend visit 5 (15 months) before the last patient has attended this visit will be asked to attend additional visits (visits 6+) until the last patient has attended visit 5. Clinical examination will be performed, for applicable patients, at 3 month intervals until the end of the study. This will be a maximum of two years, i.e. no more than eight additional visits. Laboratory assessments will be performed at screening 3, 4, 6, 9, 12 and 15 months after baseline, and for applicable patients additionally at 3 month intervals until end of study. MRI will be performed (T1-weighted and T2-weighted) at randomisation (3 months after baseline) and 12 months hereafter.

Conditions

Multiple Sclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

1

interferon beta-1a and Simvastatin

Group Type: EXPERIMENTAL

Interferon-beta-1a

Intervention Type: DRUG

dosage and frequency as per label

Simvastatin

Intervention Type: DRUG

dosage and frequency as per Biogen Idec protocol

2

Interferon beta-1a and Placebo

Group Type: PLACEBO_COMPARATOR

Interferon-beta-1a

Intervention Type: DRUG

dosage and frequency as per label

Placebo

Intervention Type: DRUG

dosage and frequency the same as simvastatin as per Biogen Idec Protocol

Interventions

Interferon-beta-1a

dosage and frequency as per label

Intervention Type: DRUG

Simvastatin

dosage and frequency as per Biogen Idec protocol

Intervention Type: DRUG

Placebo

dosage and frequency the same as simvastatin as per Biogen Idec Protocol

Intervention Type: DRUG

Other Intervention Names

Avonex

Eligibility Criteria

Inclusion Criteria

• Is between the age of 18 and 55 years (both included)
• Relapsing-remitting MS according to Poser criteria (CDMS or LSDMS) 22 or definite MS according to McDonald criteria 23
• Disability equivalent to an EDSS of 5.5 or less 21
• Clinical activity defined as at least one reported or documented relapse within the last year
• Patient must be prepared to and considered able to follow the protocol during the whole study period and to attend the planned visits, even if the treatment has to be withdrawn

Exclusion Criteria

• Any condition that might give rise to similar symptoms as MS
• Immunomodulatory or immunosuppressive treatment for MS prior to inclusion into the study (prior pulse steroid treatment for relapses is allowed)
• Treatment with glucocorticoids or ACTH later than one month prior to inclusion into the study, i.e. at the screening visit
• Onset of a relapse within one month prior to inclusion into the study, i.e. at the screening visit
• History of major depression
• Alcohol or drug dependency
• Cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (NYHA III or IV)
• Significant hypertension (BP > 180/110 mmHg)
• Renal insufficiency defined as serum creatinine > 1.5 times the upper normal reference limit
• Total plasma cholesterol < 3.5 mmol/L
• Any medical illness requiring treatment with systemic corticosteroids
• Any systemic disease that can influence the patient's safety and compliance, or the evaluation of the disability
• Women who are pregnant, breast-feeding or have the possibility for pregnancy during the study. To avoid pregnancy, women have to be postmenopausal, surgically sterile, sexually inactive or practice reliable contraception

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biogen

INDUSTRY

Sponsor Role: lead

Responsible Party

Biogen Idec

Locations

Coordinating Research Site

Copenhagen, , Denmark

Countries

Denmark

References

Sorensen PS, Lycke J, Eralinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmestrom C, Stenager E, Sellebjerg F, Sondergaard HB; SIMCOMBIN study investigators. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011 Aug;10(8):691-701. doi: 10.1016/S1474-4422(11)70144-2.

Reference Type: DERIVED

PMID: 21742556 (View on PubMed)

Other Identifiers

SIMCOMBIN

Identifier Type: -

Identifier Source: org_study_id